Samsung Bioepis — Biosimilars Portfolio
Provider Samsung Bioepissamsungbioepis.com
Founded 2012
Sells To —
Pricing Model —
Ownership —
Samsung Bioepis's biosimilars portfolio includes etanercept, adalimumab, infliximab, trastuzumab, and aflibercept products.
Samsung Bioepis commercializes biosimilars including etanercept (Benepali), adalimumab (Imraldi), infliximab (Flixabi), and trastuzumab (Ontruzant).
The company launched OPUVIZ, its aflibercept biosimilar, in 2026, adding an ophthalmology product to the portfolio.
Bionovis

Bionovis — Biologic and Biosimilar Medicines
bionovis.com.br
Cristália

Biotechnology APIs & Biosimilars
cristalia.com.br
| Attribute | Samsung Bioepis — Biosimilars Portfolio | Bionovis — Biologic and Biosimilar Medicines | Biotechnology APIs & Biosimilars | |
|---|---|---|---|---|
| Provider | ||||
| Founded | 2012 | 2012 | 1972 | |
| Sells To | — | — | Consumers, Hospitals | |
| Pricing Model | — | — | Product Sales | |
| Ownership | — | — | Private |
Provider Samsung Bioepissamsungbioepis.com
Founded 2012
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 2012
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 1972
Sells To Consumers, Hospitals
Pricing Model Product Sales
Ownership Private


Biocon's biosimilars portfolio spans trastuzumab, bevacizumab, pegfilgrastim, adalimumab, etanercept, and aflibercept products.
Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.


Biopharma business unit of Fresenius Kabi Brasil offering biosimilar medicines in Brazil.

Biocon's biosimilars portfolio spans trastuzumab, bevacizumab, pegfilgrastim, adalimumab, etanercept, and aflibercept products.

Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.
Biopharma business unit of Fresenius Kabi Brasil offering biosimilar medicines in Brazil.

Truxima is a rituximab biosimilar medicine used in blood cancer and autoimmune care.
